SEARCH

SEARCH BY CITATION

Figure S1. Expression of different Aldh isoforms in mouse cerebellar tissue at different developmental timepoints. RNA from whole cerebellar of indicated ages was extracted and quantitatively explored by GeneChip analyses. Data were obtained from the Cerebellar Developmental Transcriptome Database (CDTDB, http://www.cdtdb.brain.riken.jp/CDT/Top.jsp).

Figure S2. Expression of different Aldh isoforms in mouse cerebellar tissue at different developmental timepoints. RNA from whole cerebellar of indicated ages was extracted and quantitatively explored by GeneChip analyses. Graphs are build from reanalyzed data from previously published research (10).

Figure S3. Kaplan–Meier survival plot for GBM samples with differential ALDH1A1 gene expression. Publicly available data from the Repository of Molecular Brain Neoplasia Data (Rembrandt; http://caintegrator-info.nci.nih.gov/rembrandt) were analyzed for gene expression of ALDH1A1 in GBM patients. Rembrandt allows categorization of patients into three groups (up-regulated, intermediate and down-regulated). Up-regulation (>2×) was only observed in four patients and therefore not considered for statistical analysis. Intermediate expression (n = 96) was therefore considered as higher and down-regulation (n = 81) as lower expression. Affymetrix gene expression analysis of ALDH1A1 [Reporter: 212224_at (Lowest Geometric Mean Intensity)] in GBM shows a tendency toward better prognosis for patients with higher vs. lower expression [Log-rank P-value = 0.071 (for significance of difference of survival between group of samples)].

Table S1. Summary of clinical data, molecular genetic signatures (MGMT promoter status, ALDH expression) and individual treatment modalities of all analyzed patients. Histological and molecular genetic analysis was acquired by tumor resection (TR) or stereotactical serial biopsy (SBx). First-line therapy consisted either of radiation therapy (RT) alone (mainly before 2005) or of radiotherapy with concomitant chemotherapy with temozolomide (RCTx) followed by temozolomide (TMZ 5/28 days) for at least six cycles according to the EORTC/NCIC-protocol (26). In case of tumor recurrence, individual treatment concepts were rendered in order to meet the requirements for a personalized cancer therapy. Treatment options included re-resection (ReTR), re-irradation (ReRT) with/without chemotherapy (+TMZ) or anti-angiogenic therapy with bevacizumab (+BEV) as well as a dose-intensified TMZ protocol (TMZ 7/7 = one week on − one week off) or other chemotherapy protocols like PC(V) [procarbazin + CCNU (+vincristin)] or ACNU. Moreover, local therapies included microsurgical BCNU-wafer implantation and stereotactical interstitial photodynamic therapy (iPDT) as well as stereotactical brachytherapy (SBT) using transient 125-iodine seeds. Only few patients had received additional study medication as they were included into clinical trials [IL-13 convection enhanced delivery (CED), cilengitide (CIL), nimotizumab (NIM), imatinib (IMA) and hydroxyurea (HU)]. In case of failure of all reasonable tumor-specific therapies, supportive and palliative care (SPC) was initiated. If patients were lost to clinical follow-up (LTFU), the last status was acquired by chart review or contact with the family doctor. A change in therapy is indicated by an arrow ([RIGHTWARDS ARROW]).

FilenameFormatSizeDescription
bpa592_sm_FigureS1-3.ppt184KSupporting info item
bpa592_sm_tableS1.doc244KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.